@ash-hematology.bsky.social
Thank you #ASH24 for a fun meeting and all the education. Also, thank you for easy CME process:
Step ONE: Pay $30 before anything else. OK
Step TWO: Pick and EVALUATE EACH session you attended. Fine makes sense.
Step THREE: Write a statement
@ash-hematology.bsky.social
Thank you #ASH24 for a fun meeting and all the education. Also, thank you for easy CME process:
Step ONE: Pay $30 before anything else. OK
Step TWO: Pick and EVALUATE EACH session you attended. Fine makes sense.
Step THREE: Write a statement
#CeleBMTies
Dr. Steve Devine needs no introduction. One of the greatest BMT investigators of my time. Now starting and running transformative trials through the @nmdp-org.bsky.social
#CeleBMTies
Dr. Steve Devine needs no introduction. One of the greatest BMT investigators of my time. Now starting and running transformative trials through the @nmdp-org.bsky.social
#ASH24
#BestSlideSummaries
#WhatAreWeCallingThese skies? Posts? Blues?
#ASH24
#BestSlideSummaries
#WhatAreWeCallingThese skies? Posts? Blues?
#BMTsm
#CeleBMTies
#BMTmemories
Dr. Mukta Arora spotted at ASH. Seminal contributions to the field of GVHD.
#BMTsm
#CeleBMTies
#BMTmemories
Dr. Mukta Arora spotted at ASH. Seminal contributions to the field of GVHD.
#ASH24
#BMTsm
ash.confex.com/ash/2024/web...
#ASH24
#BMTsm
ash.confex.com/ash/2024/web...
GLP-2 agonist for treatment of aGVHD. 31 patients, mostly with G 3/4 GVHD. ORR ~50% with durable CRs of ~30%. 11 patients with G5 events - unrelated to study drug. Unmet need for non-immunosuppressive therapies
#ASH24
#BMTsm
GLP-2 agonist for treatment of aGVHD. 31 patients, mostly with G 3/4 GVHD. ORR ~50% with durable CRs of ~30%. 11 patients with G5 events - unrelated to study drug. Unmet need for non-immunosuppressive therapies
#ASH24
#BMTsm